The U.S. Food and Drug Administration (FDA) approved a new drug, anifrolumab (Saphnelo), for moderate to severe systemic lupus erythematosus (SLE). This is the first type 1 interferon receptor antagonist for lupus.
Gradually weaning off steroids may lead to less flares among lupus patients in remission than staying on a low-dose treatment, new research found.
In our Arthritis Awareness Month campaign that sought to raise awareness of the challenges of living with invisible illnesses, community members shared how they get others to understand a condition that can’t always be seen. Many said that they have given up on trying to explain their invisible illness to people who don’t want to understand.
A new study suggests that a one-unit increase in disease activity scores might increase risk of organ damage and early mortality for lupus patients.
Depression is common with lupus, but engaging in even just a little physical activity may significantly reduce your risk.
The medication helped improve kidney function in people with lupus nephritis significantly compared with those taking a placebo.
A new study shows that lupus patients who need to take hydroxychloroquine can be reassured that it does not have a significant risk for serious heart toxicity.
New research shows that use of hydroxychloroquine did not predict prolonged QTc, a key measure of heart rate.
New research shows there is a need for aggressive preventive care to decrease racial health disparities and improve outcomes for lupus patients.
In a recent study, 86 percent of people with lupus and 72 percent of rheumatologists treating lupus agreed that having people fill out short surveys about fatigue, pain, and more helped improve communication.